{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:58:42Z","timestamp":1787497122229,"version":"build-2736575974"},"reference-count":25,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["NHMRC 2010-1012"],"award-info":[{"award-number":["NHMRC 2010-1012"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011369","name":"Royal Australian and New Zealand College of Ophthalmologists","doi-asserted-by":"publisher","award":["2007-2009"],"award-info":[{"award-number":["2007-2009"]}],"id":[{"id":"10.13039\/100011369","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>To describe baseline characteristics and 12-month outcomes with vascular endothelial growth factor (VEGF) inhibitors of treatment-na\u00efve hemiretinal vein occlusion (HRVO) compared with branch (BRVO) and central (CRVO) variants in routine clinical care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A database observational study recruited 79 HRVO eyes, 590 BRVO eyes and 344 CRVO eyes that initiated therapy over 10 years. The primary outcome was mean change in visual acuity (VA\u2014letters read on a logarithm of minimal angle of resolution chart) at 12 months. Secondary outcomes included mean change in central subfield thickness (CST), injections and visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, mean VA in HRVO (53.8) was similar to CRVO (51.9; p=0.40) but lower than BRVO (59.4; p=0.009). HRVO eyes improved to match BRVO eyes from soon after treatment started through 12 months. Mean change in VA was greater in HRVO (+16.4) than both BRVO (+11.4; p=0.006) and CRVO (+8.5; p&lt;0.001). Mean change in CST in HRVO (\u2212231\u2009\u00b5m) was similar to CRVO (\u2212259\u2009\u00b5m; p=0.33) but greater than BRVO eyes (\u2212151\u2009\u00b5m; p=0.003). The groups had similar median burdens of eight injections and nine visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HRVO generally experienced the greatest mean change in VA of the three types of RVO when treated with VEGF inhibitors, ending with similar 12-month VA and CST to BRVO despite starting closer to CRVO. Inclusion of HRVO in BRVO or CRVO cohorts of clinical trials would be expected to proportionally inflate and skew the visual and anatomic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjophthalmol-2021-320482","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T13:25:16Z","timestamp":1643117116000},"page":"842-848","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry"],"prefix":"10.1136","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-4679","authenticated-orcid":false,"given":"Adrian Robert","family":"Hunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-9803","authenticated-orcid":false,"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-0821","authenticated-orcid":false,"given":"Ian L","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-1987","authenticated-orcid":false,"given":"Alessandro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodorus","family":"Ponsioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9688-4845","authenticated-orcid":false,"given":"Pierre-Henry","family":"Gabrielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"O'Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavol","family":"Kusenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socorro","family":"Alforja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"2023051902150763000_107.6.842.1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1984.01040030069038"},{"key":"2023051902150763000_107.6.842.2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1980.01020040452011"},{"key":"2023051902150763000_107.6.842.3","first-page":"241","article-title":"Hemi-central retinal vein occlusion. pathogenesis, clinical features, natural history and incidence of dual trunk central retinal vein","volume":"102 (pt 2","author":"Chopdar","year":"1982","journal-title":"Trans Ophthalmol Soc U K"},{"key":"2023051902150763000_107.6.842.4","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(84)90316-7"},{"key":"2023051902150763000_107.6.842.5","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/archophthalmol.2012.2728","article-title":"Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (score) study: score study report 14","volume":"130","author":"Scott","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"2023051902150763000_107.6.842.6","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"key":"2023051902150763000_107.6.842.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.021"},{"key":"2023051902150763000_107.6.842.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.08.031"},{"key":"2023051902150763000_107.6.842.9","first-page":"Cd009510","article-title":"Anti-Vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion","volume":"7","author":"Shalchi","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2023051902150763000_107.6.842.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.01.042"},{"key":"2023051902150763000_107.6.842.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.012"},{"key":"2023051902150763000_107.6.842.12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.oret.2019.12.019","article-title":"Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion: the bevacizumab to ranibizumab in retinal vein occlusions (BRVO) study, a randomized trial","volume":"4","author":"Vader","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"2023051902150763000_107.6.842.13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2147\/OPTH.S7631","article-title":"Retinal vein occlusion: pathophysiology and treatment options","volume":"4","author":"Karia","year":"2010","journal-title":"OPTH"},{"key":"2023051902150763000_107.6.842.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2023051902150763000_107.6.842.15","unstructured":"R Core Team . The R project for statistical computing. Vienna, Austria: R foundation for statistical computing, 2021. https:\/\/www.R-project.org\/"},{"key":"2023051902150763000_107.6.842.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.022"},{"key":"2023051902150763000_107.6.842.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"2023051902150763000_107.6.842.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.038"},{"key":"2023051902150763000_107.6.842.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.035"},{"key":"2023051902150763000_107.6.842.20","article-title":"Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry","volume":"123","author":"Hunt","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"2023051902150763000_107.6.842.21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/OPTH.S104459","article-title":"Grid laser with modified pro re NatA injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2","volume":"10","author":"Narayanan","year":"2016","journal-title":"OPTH"},{"key":"2023051902150763000_107.6.842.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.022"},{"key":"2023051902150763000_107.6.842.23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ophtha.2016.09.038","article-title":"SCORE2 report 2: study design and baseline characteristics","volume":"124","author":"Scott","year":"2017","journal-title":"Ophthalmology"},{"key":"2023051902150763000_107.6.842.24","first-page":"27","article-title":"Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases","volume":"1","author":"Green","year":"1981","journal-title":"Retina"},{"key":"2023051902150763000_107.6.842.25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1442-9071.1991.tb00668.x","article-title":"Collateral formation in hemicentral retinal vein occlusion","volume":"19","author":"McAllister","year":"1991","journal-title":"Aust N Z J Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2021-320482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:21:11Z","timestamp":1684473671000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2021-320482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,19]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bjophthalmol-2021-320482"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2021-320482","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]}}}